ReviewMolecular psychiatry2019
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches.
Review in Molecular psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 5 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Genetic variation associated with depression in Latin American populations: a systematic review of single-nucleotide variants.Frontiers in psychiatry · 2026Pooled it
- Nitrous oxide for the treatment of depression: a systematic review and meta-analysis.EBioMedicine · 2025Pooled it
- Ketamine in treating opioid use disorder and opioid withdrawal: a scoping review.Frontiers in psychiatry · 2025Pooled it
- Endogenous mu-opioid modulation of social connection in humans: a systematic review and meta-analysis.Translational psychiatry · 2024Pooled it
- Mood and Anxiety Symptoms in Persons Taking Prescription Opioids: A Systematic Review with Meta-Analyses of Longitudinal Studies.Pain medicine (Malden, Mass.) · 2022Pooled it
- Opioids diminish the placebo antidepressant response: Observational post hoc findings from a randomized controlled ketamine trial.Journal of affective disorders · 2025Trial
- Opioid consumption frequency and its associations with potential life problems during opioid agonist treatment in individuals with prescription-type opioid use disorder: exploratory results from the OPTIMA Study.Harm reduction journal · 2025Trial
- Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.Substance use & misuse · 2022Trial
- Opioid Exposure Negatively Affects Antidepressant Response to Venlafaxine in Older Adults with Chronic Low Back Pain and Depression.Pain medicine (Malden, Mass.) · 2020Trial
- κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine.Journal of clinical psychopharmacologyTrial
- Targeting Mu Opioid Receptor Neurons of the Habenula to Limit Naloxone Aversion.Biological psychiatry · 2026Article
- Kappa-Opioid Receptor Antagonism Prolongs the Antidepressant Effects of Ketamine in Adult Mice with Depression-like Behavior Induced by Adolescent Chronic Unpredictable Stress.International journal of molecular sciences · 2026Article
- Review
- Anxiolytic and antidepressant effects of astaxanthin: behavioral and mechanistic insights in a rat model.Frontiers in pharmacology · 2026Article
- Updated Freudian drive theory: childhood trauma, epigenetics, serotonin and beta endorphin.Frontiers in psychiatry · 2026Article
- Assessing behavioural economic demand for morphine after an acute dose in individuals with- and without childhood trauma: a double-blind, randomised, controlled trial.Psychopharmacology · 2025Article
- Ketamine Evokes Acute Behavioral Effects Via μ Opioid Receptor-Expressing Neurons of the Central Amygdala.Biological psychiatry · 2025Article
- Study on subtyping and Traditional Chinese Medicine treatment of depression based on machine learning and text mining.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- The association between prenatal depression and persistent postpartum pharmaceutical opioid use in six US states.Pregnancy (Hoboken, N.J.) · 2025Article
- Mechanism of antidepressant action of ketamine and differences between its two enantiomers.Journal of anesthesia and translational medicine · 2025Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
The United States is in the midst of an opioid addiction and overdose crisis precipitated and exacerbated by use of prescription opioid medicines. The majority of opioid prescriptions are dispensed to patients with comorbid mood disorders including major depressive disorder (MDD). A growing body of research indicates that the endogenous opioid system is directly involved in the regulation of mood and is dysregulated in MDD. This involvement of the endogenous opioid system may underlie the disproportionate use of opioids among patients with mood disorders. Emerging approaches to address endogenous opioid dysregulation in MDD may yield novel therapeutics that have a low or absent risk of abuse and addiction relative to µ-opioid agonists. Moreover, agents targeting the endogenous opioid system would be expected to yield clinical benefits qualitatively different from conventional monaminergic antidepressants. The development of safe and effective agents to treat MDD-associated endogenous opioid dysregulation may represent a distinct and currently underappreciated means of addressing treatment resistant depression with the potential to attenuate the on-going opioid crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.